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recession and the IPHA agreement on the rate of positive reimbursement made by 
the NCPE. We also tested whether the new agreement had an impact on the time-
to-reimbursement using a linear regression model. Results: The results of the 
logit model suggest that neither the economic recession nor the agreement had 
any statistically significant impact on the probability of reimbursement. However, 
there was some evidence that the time-to-reimbursement was reduced after the 
agreement (p< 0.10). ConClusions: Although the analysis suggests that these two 
events had no impact on the rate of reimbursement it is possible that the reimburse-
ment price of new drugs may have decreased over this period which could have 
facilitated reimbursement. Unfortunately, details of the final price of medicines are 
not always known in the Irish system and it is therefore not possible to test this 
hypothesis using currently available data. Our analysis of time-to-reimbursement 
suggests that the new agreement may have satisfied one of its main objectives in 
getting new medicines onto the market sooner.
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objeCtives: Offering a standardized HTA process model through economic evalu-
ation of IDTs in the Turkish health care system. Methods: Current regulations on 
evaluation of innovative drug technologies through the reimbursement process are 
defined via a process flow scheme. A stepwise model is proposed to cover a stand-
ardized HTA system within the economic evaluation through an independent HTA 
body (Model HTA Authority). Results: In the current system, economic evaluation 
content of a reimbursement application dossier is evaluated by Social Security 
Institution (SSI) through Technical and Main Commissions respectively. However 
this evaluation process is not standardized with respect to main variables such as 
scientific methodologies, timelines and responsibilities. This study offers a model, 
which initiates a re-defined application step for economic evaluation content 
of a IDT reimbursement dossier; parallel application to SSI and an independent 
HTA body (Model HTA Authority). Therefore, the Main Commission in SSI will be 
able to combine a general evaluation from the Technical Commission and an HTA 
report of the IDT by an independent HTA body. These reports will be available to 
owners of reimbursement applications until announcement of a final decision of 
SSI, and will become publicly available afterwards. ConClusions: IDTs are not 
involved in a standardized HTA process in the current Turkish health care system. 
However, pharmacoeconomic analysis reports are requested by SSI for reimburse-
ment applications of IDTs. This study offers a model, which includes a standard-
ized HTA process for IDT in the Turkish health care system. Applicability of this 
model may be tested through pilot projects and further steps may be defined for 
further excellence.
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objeCtives: To identify, from a private payer’s perspective, the required elements 
to include in a pharmacoeconomic model and a budget impact analysis and com-
pare them to that of the public payers’ requirements. The secondary objective was 
to determine the preferred components to present in a submission regarding pri-
vate payers. Methods: A survey was sent to 21 submission reviewers from 14 
private insurance companies offering drug reimbursement, using an online sur-
vey builder, KwikSurveys. The survey included 15 questions divided in 5 sections: 
General information, Clinical information, Pharmacoeconomic evaluation, Budget 
impact analysis and General appreciations. Results: Nine reviewers from eight 
different companies, which represent 80% of the Canadian private payer market 
shares, responded to the survey. Results showed that 67% of participants follow the 
Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines for eco-
nomic evaluations. 88% of participants prefer a cost-effectiveness evaluation, while 
75% prefer a cost-benefit evaluation. 100% of the participants would like direct drug 
costs and the indirect costs related to loss of productivity due to reduced working 
capacity to be included in the pharmacoeconomic model. 75% would like the costs 
to employer to hire and train replacement worker, the costs of premiums paid to, 
as well as benefits received from, private insurers to also be included in the model. 
63% of the participants would like to see a population data-based model for their 
budget impact analysis. Similarly, 63% of the participants prefer a time horizon 
of 3 years for the budget impact analysis. ConClusions: The parameters to be 
considered in a submission sent to private payers are different from public payers’ 
requirements. The perspective of the pharmacoeconomic model should be that of 
a private payer and the budget impact analysis should only consider a population 
covered by private payers.
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objeCtives: Market access for innovative new technologies can be complex 
and time consuming. As cost-containment pressures in the European Union (EU) 
intensify, evidentiary hurdles to justify new point-of-care (POC) tests continue to 
grow. Decentralized health care decision making can also be a significant hurdle. 
This study aimed to characterize the process and identify challenges for Health 
Technology Assessment (HTA), pricing, reimbursement, and market access for a 
new POC test in the EU-5 countries. Methods: We conducted desktop research of 
dence. Both organizations reached the same assessment regarding clinical benefit 
in only 13 cases (52%). ConClusions: AMNOG implements a more rigorous process 
with respect to clinical evidence assessment compared to SMC. All AMNOG deci-
sions are positive; however final prices may resemble generic prices for products 
that demonstrate low additional benefit (“Festbetragsgruppen”). In comparison, 
a negative decision by SMC warrants re-submission and re-assessment of the set 
price for successful drug reimbursement. Orphan drugs are assessed as normal 
products in Scotland and may be rejected on the grounds of economic evidence, 
while in Germany the additional benefit is presumed and price negotiation starts 
automatically. Furthermore, the SMC assessment process starts later than the 
AMNOG process.
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While pharmaceutical sales in mature economies are declining, in emerging mar-
kets they have been expanding rapidly, with growth rates in double figures. Here we 
focus on market access in BRIC (Brazil, Russia, India and China) which together rep-
resent just over 40% of the world population.objeCtives: To identify the processes 
and key stakeholders involved in gaining market access in BRIC; to assess the impor-
tance of health technology assessment (HTA) in gaining reimbursement in these 
countries; to identify opportunities and challenges to market access. Methods: 
A review was conducted to identify the current processes and key stakeholders in 
market access in the BRIC countries and to identify favourable and unfavourable fac-
tors to market access. Results: The licensing and reimbursement processes vary 
in the BRIC countries. Brazil follows processes similar to those in Western Europe, 
including HTA and public consultation as part of the reimbursement application. In 
China, the licensing process can take 4-6 years, though fast-tracking for innovative 
drugs has recently been introduced. Russia, China and India do not yet rely on HTA 
for reimbursement decisions. In India plans to use “pharmacoeconomic principles” 
in setting prices of new molecules have been announced. Opportunities in all these 
countries result from increasing affluence and life expectancy and the diseases 
associated with these. Some challenges to market access are: poor IP protection; 
protectionist measures; compulsory licensing; drive to use generics or biosimilars, 
often produced locally; price controls; variable health insurance/NHS coverage; 
and limited budgets for prescription drugs. ConClusions: HTA is now common 
practice in Brazil, but not yet in Russia, India or China. Although demand for new 
drugs is increasing in these markets, protectionism measures, competition from 
generics and budget constraints due to the increased burden and requirement for 
new high priced drugs present a challenge when accessing the pharmaceutical 
market in BRIC countries.
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objeCtives: The gold-standard pivotal trial design has three arms with experi-
mental medicine, placebo and active control however, often marketing authorisa-
tion is granted on placebo controlled (PLAc) trial(s). While PLAc trials are often 
still acceptable to the European Clinical Trials Directive and European Medicines 
Agency (EMA), they are less acceptable to Health Technology Assessment (HTA) 
bodies. The latter request an (in)direct comparison vs. the relevant active 
comparator(s) (AC) to demonstrate the added value of existing standard of care. 
We have investigated the hurdles encountered during HTA assessments for those 
drugs with marketing authorization based solely on PLAc studies. Methods: We 
identified those drugs approved since 2010 by EMA based only on PLAc trials. We 
then reviewed the HTA assessments for these drugs in France (HAS), Germany 
(G-BA) and the UK (NICE and SMC) and compared these HTA assessments to others 
where the trial included an AC. Results: Applications for 41 (45 indications) of the 
220 drugs approved by EMA between 2010 and end of 2012 were based exclusively 
on PLAc trials. The number of indications already assessed and recommended 
(percentage) by HTA bodies are 19 and 11 (58%) for NICE, 33 and 18 (55%) for SMC, 
24 and 20 (83%) for HAS, and 18 and 12 (67%) for G-BA. When compared to all 
HTAs irrespective of comparator being placebo or AC assessed since 2010, lack of 
an AC seemed to have no impact in HAS (83% vs 75% favorable opinion among all 
assessments) and G-BA (67% vs 58%) assessments but had a negative impact on 
SMC (55% vs 85%) and NICE (58% vs 64%) recommendations. ConClusions: The 
impact of no direct comparison with an AC varies across countries. The analysis 
seems to indicate that in absence of head-to-head data HTA agencies will accept 
indirect evidence against the right AC.
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objeCtives: To assess the impact of the Irish economic recession (September, 2008) 
and the Irish Pharmaceutical Healthcare Association agreement (IPHA; November, 
2012) on the probability of reimbursement decided by the National Centre for 
Pharmacoeconomic Evaluation (NCPE). We also aim to test whether the new IPHA 
agreement reduced the time-to-reimbursement for new medicines in the General 
Medical Services (GMS) and High Tech Drug Scheme (HTDS). Methods: A database 
of all NCPE decisions since 2006 to present was compiled from publically available 
NCPE decision reports and a logistic model was used to test the occurrence of the 
